Calibration and optimization of p53, WT1, and Napsin A Immunohistochemistry ancillary tests for histotyping of ovarian carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) experience

International Journal of Gynecological Pathology

Volumn 35, Issue 3, 2016, Pages 209-221

  Lee, Sandra ^a   Piskorz, Anna M ^e   Le Page, Cécile ^b   Mes Masson, Anne Marie ^b   Provencher, Diane ^c   Huntsman, David ^c   Chen, Wenqian ^a   Swanson, Paul E ^a   Gilks, C Blake ^d   Köbel, Martin ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

CIQC; Histotype; Immunohistochemistry; Napsin A; Ovarian cancer; p53 WT1

Indexed keywords

MONOCLONAL ANTIBODY; NAPSIN A; POLYCLONAL ANTIBODY; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; WT1 PROTEIN; ASPARTIC PROTEINASE; NAPSA PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; WT1 PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; MISSENSE MUTATION; NONSENSE MUTATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SPLICE SITE MUTATION; STAINING; TISSUE MICROARRAY; CALIBRATION; CANADA; CARCINOMA; CLASSIFICATION; GENETICS; GOOD LABORATORY PRACTICE; METABOLISM; MUTATION; OVARY TUMOR; PATHOLOGY; QUALITY CONTROL;

ASPARTIC ACID ENDOPEPTIDASES; BIOMARKERS, TUMOR; CALIBRATION; CANADA; CARCINOMA; FEMALE; HISTOLOGY; HUMANS; IMMUNOHISTOCHEMISTRY; LABORATORY PROFICIENCY TESTING; MUTATION; OVARIAN NEOPLASMS; QUALITY CONTROL; TUMOR SUPPRESSOR PROTEIN P53; WT1 PROTEINS;

EID: 84947998749     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000251     Document Type: Article

References (39)

1. Chui MH, Ryan P, Radigan J, et al. The histomorphology of Lynch-syndrome associated ovarian carcinomas: toward a subtype specific screening strategy. Am J Surg Pathol 2014;38:1173-81.
2. Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of the ovarian surface. Appl Immunohistochem Mol Morphol 2004;12:122-6.
3. Tabrizi AD, Kalloger SE, Köbel M, et al. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 2010;29:99-107.
4. Geza A, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004;23:110-8.
5. Waldstrom M, Grove A. Immunohistochemical expression of Wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med 2005;129: 85-8.
6. Motohiko S, Toshihiko T, Yasushi T, et al. Immunohistochemical detection of the Wilms tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-63.
7. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immnohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 2005;36:195-201.
8. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid carcinoma. Histopathology 2004;44:109-15.
9. Fadare O, James S, Desouki MM, et al. Coordinate patterns of ER, PR and WT1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Ann Diagn Pathol 2013;17:430-3.
10. Yamashita Y, Nagasaka T, Naiki-Ito A, et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol 2015;28:111-7.
11. Fadare O, Zhao C, Khabele D, et al. Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemace (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumors. Pathology, 47:105-11.
12. Skirnisdottir I, Bjersand K, Akerud H, et al. Napsin A as a marker of clear cell ovarian carcinoma. BMC Cancer 2013;13:524.
13. Kandalaft P, Gown A, Isacson A. The lung restricted marker Napsin A is highly expressed in clear cell carcinomas of the ovary. Am J Clin Pathol 2014;142:830-6.
14. Yemelyanova A, Vang R, Kshirsagar M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 2011;24:1248-53.
15. Köbel M, Reuss A, du Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222:191-8.
16. Köbel M, Kalloger SE, Lee S, et al. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev 2013;22:1677-86.
17. Kalloger SE, Köbel M, Leung S, et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol 2011;24:512-21.
18. Köbel M, Bak J, Bertelsen BI, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 2014;64:1004-13.
19. Köbel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
20. Lassus H, Leminen A, Lundin J, et al. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 2003;91:504-12.
21. Min WK, Park MH, Hong SR, et al. Clear cell carcinoma of the ovary: a multi-institutional study of 129 cases in Korea with prognostic significance of Emi1 and Galactin-3. Int J Gynecol Pathol 2013;32:3-14.
22. Stewart CJR, Walsh MD, Budgeon CA, et al. Immunophenotypic analysis of ovarian endometrioid adenocarcinoma: correlation with KRAS mutation and the presence of endometriosis. Pathology 2013;45:559-66.
23. Lai CR, Hsu CY, Chen YJ, et al. Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1beta, p53, PTEN, BAF250a, and COX-2. J Chin Med Assoc 2013;76:629-34.
24. Köbel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell carcinoma and high grade serous carcinoma of the ovary. Am J Surg Pathol 2009;33:14-21.
25. Le Page C, Köbel M, de Ladurantaye M, et al. Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. Biopresev Biobank 2013;11:83-93.
26. Köbel M, Piskorz A, Liu S, et al. Immunohistochemistry predicts presence and type of TP53 mutation in high-grade serous carcinoma. Cancer Res 1158;74:1535. Abstract.
27. Wen WH, Reles A, Runnebaum IB, et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999;18:29-41.
28. Shahin MS, Hughes JH, Sood AK, et al. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000;89:2006-17.
29. Miller K, Price JH, McClelland RH, et al. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J Clin Pathol 2008;61:652-7.
30. Sundov D, Caric A, Mrklic I, et al. p53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. Diagn Pathol 2013;8:21. 1-9.
31. Altman AD, Nelson GS, Ghatage P, et al. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian highgrade serous carcinoma from low-grade serous ovarian tumors. Mod Pathol 2013;26:1255-63.
32. Köbel M, Turbin D, Kalloger SE, et al. Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. Int J Gynecol Pathol 2011;30: 366-71.
33. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol 2012;31:243-53.
34. Singh N, Leen SL, Han G, et al. Expanding the morphologic spectrum of differentiated Vin (dVIN) through detailed mapping of cases with p53 loss. Am J Surg Pathol 2015; 39:52-60.
35. Singer H, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and highgrade serous carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005;29: 218-24.
36. MacKenzie R, Kommoss S, Winterhoff BJ, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer 2015;15:415.
37. Wojinarowicz PM, Oros KK, Quinn MC, et al. The genomic landscape of TP53 and p53 annotated high grade serous carcinomas from a defined founder population associated with patient outcome. PLoS One 2012;7:e45484.
38. Allan LA, Campbell MK, Milner BJ, et al. The significance of p53 mutation and over expression in ovarian cancer prognosis. Int J Gynecol Pathol 1996;6:483-90.
39. Klemi P, Pylkkanen L, Kiilholma P, et al. P53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.